Not yet recruitingPhase 4NCT07334535

Isa-VRD in TIE HRMM

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking Union Medical College Hospital
Principal Investigator
Junling Zhuang
Peking Union Medical College, department of hematology
Intervention
Isatuximab, bortezomib, lenalidomide, dexamethason(drug)
Enrollment
117 enrolled
Eligibility
18-80 years · All sexes
Timeline
2026 – 2029

Study locations (1)

Collaborators

Handan Central Hospital · Inner Mongolia People's Hospital · The Affiliated Hospital of Qingdao University · Hebei Medical University Third Hospital · North China University of Science and Technology · China-Japan Union Hospital, Jilin University · Cangzhou Central Hospital · Yantai Yuhuangding Hospital · Shengjing Hospital · Second Hospital of Shanxi Medical University · Beijing Chao Yang Hospital · Beijing Jishuitan Hospital · Henan Cancer Hospital · Beijing Hospital · Xuanwu Hospital, Beijing · Shandong Cancer Hospital and Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07334535 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials